What is the recommended prophylactic dose of enoxaparin (low‑molecular‑weight heparin) for a pregnant patient, and how should the dose be adjusted for a BMI ≥ 40 kg/m²?

Prophylactic Enoxaparin Dosing in Pregnancy

For standard prophylaxis in pregnant patients, use enoxaparin 40 mg subcutaneously once daily; for pregnant patients with class III obesity (BMI ≥40 kg/m²), use intermediate-dose enoxaparin 40 mg subcutaneously every 12 hours. 1

Standard Prophylactic Dosing

The Society for Maternal-Fetal Medicine (SMFM) 2020 guidelines, endorsed by ACOG, establish low-molecular-weight heparin (LMWH) as the preferred thromboprophylactic agent in pregnancy and the postpartum period (GRADE 1C). 1 The standard prophylactic dose is:

• Enoxaparin 40 mg subcutaneously once daily 1

This dosing applies to most pregnant patients requiring pharmacologic VTE prophylaxis, including those with:

• Previous personal history of DVT or PE
• Inherited thrombophilia (high-risk or low-risk)
• Multiple VTE risk factors after cesarean delivery

Dose Adjustment for Class III Obesity (BMI ≥40 kg/m²)

When pharmacologic thromboprophylaxis is needed in pregnant women with class III obesity, use intermediate doses of enoxaparin 40 mg subcutaneously every 12 hours (GRADE 2C). 1

Rationale for Higher Dosing in Obesity

The evidence supporting this recommendation includes:

• Fixed intermediate dosing (40 mg every 12 hours) achieves more consistent prophylactic anti-Xa levels in obese women 1
• Weight-based dosing (0.5 mg/kg every 12 hours) results in anti-Xa levels more often within the desired prophylactic target range compared to fixed dosing in morbidly obese women after cesarean delivery 1
• However, it remains unknown whether these dosing strategies result in fewer actual thrombotic events 1

Important Caveats

The optimal dose for obese pregnant patients is not definitively established, and the GRADE 2C recommendation reflects uncertainty in the evidence. 1 The recommendation is based on pharmacokinetic data (anti-Xa levels) rather than clinical outcomes (actual VTE events). Some clinicians may consider weight-based dosing (0.5 mg/kg every 12 hours) as an alternative, particularly for patients with BMI ≥50 kg/m², though this approach lacks robust outcome data in pregnancy.

Alternative: Unfractionated Heparin

For patients with renal disease where LMWH clearance is impaired, unfractionated heparin (UFH) is preferred due to its shorter half-life (60-90 minutes) and renal-independent clearance. 1

UFH prophylactic dosing varies by trimester:

• First trimester: 5,000 units subcutaneously every 12 hours
• Second trimester: 7,500 units subcutaneously every 12 hours
• Third trimester: 10,000 units subcutaneously every 12 hours
• Postpartum: 5,000 units subcutaneously every 8-12 hours 1

Timing After Neuraxial Anesthesia

Critical safety consideration: Prophylactic enoxaparin 40 mg once daily may be started as early as 4 hours after epidural catheter removal but not earlier than 12 hours after the neuraxial block was performed. 1

For intermediate doses (40 mg every 12 hours), the same 4-hour post-catheter removal rule applies, but not earlier than 24 hours after the block was performed. 1 This extended interval reduces spinal/epidural hematoma risk with higher anticoagulant exposure.

Duration of Prophylaxis

For high-risk patients (prior VTE or thrombophilia), pharmacologic prophylaxis should continue for 6 weeks postpartum. 1